Mutagenicity of bisbenzimidazole derivatives.
The mutagenicities of 2,2'-(di-3-hydroxyphenyl)-1H,1H'-[5,5']-bisbenzimidazole, 2,2'-(di-4-hydroxyphenyl)-1H,1H'-[5,5']-bisbenzimidazole, 2,2'-(di-3-methoxyphenyl)-1H,1H'-[5,5']-bisbenzimidazole, 2,2'-bis-(4-nitrophenyl)-1H,1H'-[5,5']-bisbenzimidazole, 2,2'-bis-(3-nitrophenyl)-1H,1H'-[5,5']-bisbenzimidazole, 2,2'-bis-(4-methylphenyl)-1H,1H'-[5,5']-bisbenzimidazole, 2,2'-(di-4-methoxyphenyl)-1H,1H'-[5,5']-bisbenzimidazole, and 2,2'-bis-(3-methylphenyl)-1H,1H'-[5,5']-bisbenzimidazole were studied in vitro using two strains of Salmonella typhimurium with frameshift mutation (TA98) and base-pair substitution mutation (TA100) as the plate incorporation assay in the absence of metabolic activation. These compounds are currently used to treat cancer. 4-Nitrophenyl and 3-nitrophenyl compounds were found to be mutagenic on both strains of Salmonella. A clear mutagenic response was seen in nitro-bound derivatives. The mutagenic response in Salmonella test strains (TA98, TA100) and structures of molecules suggest that nitro-bound molecules could be mutagenic.
Alanyali
Filiz Susuz
FS
Department of Biology, Faculty of Science, Anadolu University, 26470 Eskişehir, Turkey. fsusuz@anadolu.edu.tr
Arici
Merve
M
Artagan
Oge
O
Işikdağ
Ilhan
I
Ozkay
Yusuf
Y
D001562:Benzimidazoles / Q000494:pharmacology*; D007700:Kinetics; D009152:Mutagenicity Tests; D009153:Mutagens / Q000494:pharmacology*; D012475:Salmonella / Q000187:drug effects* / Q000235:genetics; D013329:Structure-Activity Relationship
D001562:Benzimidazoles; D009153:Mutagens